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The Editorial on the Research Topic
Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity 
of Inflammation and Cancer
An old Indian legend tells a story about six blind men who touched an elephant. The first man who 
touched his leg said: “it is a pillar.” The second man who touched the tail said: “it is a rope.” The third 
man who touched the trunk of the elephant said: “it is a thick branch of a tree.” The fourth man who 
touched the ear said: “It is a big hand fan.” The fifth man who touched the belly said: “It is a huge wall.” 
The sixth man who touched the tusk of the elephant said: “It is a solid pipe.” Each one of them loudly 
insisted that his claim is the right one. Then wise old man arrived to the place of scene, listened to 
their arguments and said “all of you are right, but all together you identified an elephant.”
Similarly, each one of the 18 chapters of this e-book tells a different, fascinating story about the 
“biological polygamy” of hyaluronan and its receptors. Yet, this story is focused on the author’s 
specific field of interest or discipline. On the other hand, when the 18 chapters are collected in one 
e-book, each of them fosters the others and collectively a complete scene is created.
Hyaluronan or hyaluronic acid (HA), which resides in the interstitial collagenous matrices, 
increases viscosity and hydration and binds to a “link module motif ” of HA-binding proteoglycans 
(e.g., CD44) and link proteins. HA is a non-sulfated, linear glycosaminoglycan (GAG) composed 
of repeating disaccharides of (β, 1–4)-glucuronic acid (GlcUA) and (β, 1-3)-N-acetyl glucosamine 
(GlcNAc). In most tissues, native HA has a high molecular mass of 1000–10,000 kDa, with extended 
molecular lengths of 2–20 μm. HA plays crucial roles in structuring tissue architecture, in cell motil-
ity, in cell adhesion, and in proliferation processes (1, 2).
Hyaluronic acid is synthesized by three HA synthase (HAS) proteins. These generate predomi-
nantly high molecular weight-HA (HMW-HA) of between 200 and 2000 kDa. HA catabolism is 
mediated by hyaluronidases, mechanical forces, and oxidative stress (reactive oxygen and nitrogen 
species). The degradation generates different-sized HA polymers (or fragments), abbreviated low 
molecular weight-HA (LMW-HA; <200 kDa) and HA oligomers (1).
In general (exceptions do exist), LMW-HA is pro-inflammatory and pro-cancerous, whereas 
HMW-HA is anti-inflammatory and anti-cancerous. In this context, a vicious cycle is generated. 
Inflammatory conditions activate the production of HAS, which synthesizes HA. Subsequently, 
the HA is degraded by hyaluronidases and reactive oxygen species, the generation of which is also 
induced by the inflammation. The resulting cleaved HA fragments further propagate the inflamma-
tion. This perpetuating cycle can be blocked by competition with excess HMW-HA. To this end, 
Tian et al. found that naked mole-rat fibroblasts secrete HMW-HA, which is over five times larger 
(6000–12000 kDa), than human or mouse HA (500–2000 kDa). The HMW-HA accumulates in naked 
February 2016 | Volume 7 | Article 392
Naor Hyaluronic Acid and Its Receptor
Frontiers in Immunology | www.frontiersin.org
mole-rat tissues. This rodent has a lifespan exceeding 30 years and 
is resistant to cancer. Interestingly, once HMW-HA is removed 
by knocking down HAS-2, or by overexpressing hyaluronidase 
2, which cleaves HMW-HA, the naked mole-rat cells become 
susceptible to malignant transformation and form tumors (3). 
Notably, the pro-inflammatory role of LMW-HA, including HA 
fragments and oligo-HA, displays not only pathological effects 
but eventually also physiological activities, such as expression of 
β-defensins to combat microbial infections (4) or induction of 
inflammation to accelerate wound healing (5).
CD44 glycoprotein is expressed on the surface of many mam-
malian cells, including leukocytes, endothelial cells, epithelial 
cells, fibroblasts, and keratinocytes. Extensive alternative splicing 
of nine variable exons and distinct post-translational modifica-
tions generate many CD44 isoforms. Standard CD44 is the 
smallest and most abundant isoform, whereas the other variants 
are expressed in a cell-specific manner (e.g., on epithelial cells 
or keratinocytes), as well as in multiple pathologies, including 
rheumatoid arthritis, diabetes, multiple sclerosis, and cancer (2, 
6). The physiological activities of CD44 stem from its multiple 
functions, including mediating cell–cell and cell–matrix interac-
tions, cell proliferation, cell adhesion, cell migration, hemat-
opoiesis, lymphocyte activation, cell homing, cell extravasation, 
cell survival, and apoptosis, as well as epithelial–mesenchymal 
transition (EMT) (7). However, these functions can be converted 
to pathological activities when exaggerated or they escape out 
of control, like in cancer or chronic inflammation. Most of the 
CD44 studies are limited to preclinical models. However, the 
use of anti-CD44 antibodies in a few clinical trials resulted in 
life-threatening toxicity (8). Therefore, the risks vs. the benefits 
must be carefully evaluated before CD44-targeting strategies are 
translated to the clinic.
The receptor for HA-mediated motility (RHAMM or CD168), 
such as CD44, is also alternatively spliced, albeit at a much 
lower intensity. Variant forms of RHAMM are found on both 
cell surfaces and inside the cells (9). However, unlike CD44, 
RHAMM isoforms do not have the link module domain. Instead, 
they have a BX7B motif that binds HA, where “B” represents 
arginine or lysine, and “X” represents any non-acidic amino acid 
(10). RHAMM supports both malignancy and wound healing 
processes.
As CD44 supports both chronic inflammation and cancer pro-
gression in many (but not all) experimental models and human 
diseases, CD44 targeting, e.g., by antibody, was successfully docu-
mented in many preclinical studies, such as collagen-induced 
arthritis (CIA) (11). Surprisingly, we found that CD44 targeting 
by CD44 gene deletion in the embryo aggravates CIA, rather than 
ameliorating it. It appears that a CD44 redundancy process in the 
CD44 deleted embryo allows up-regulation of RHAMM, which 
replaces CD44 also during adulthood. The substituting RHAMM 
supports CIA joint inflammation more effectively than CD44 
(11), because it is a better supporter of cell migration. It is not 
surprising that CD44 targeting in the adult is not redundant, like 
in the embryo, as CD44 in the embryo displays a survival-sup-
porting function that generates pressure for ultimate RHAMM 
replacement. Such a developmental pressure does not exist in the 
adult, so that CD44 targeting is not compensated by functional 
RHAMM at this phase of life, and the therapeutic effect by CD44 
targeting, can be documented.
TLR-4, a principle innate receptor of bacterial LPS, is also 
an important receptor of HA (1). TLR-4 activates nuclear factor 
(NF)-κB protein via two major routes: a myeloid differentiation 
factor (MyD) 88-dependent pathway that acts via NF-κB to 
induce pro-inflammatory cytokines and a MyD88-independent 
pathway that acts via type I interferons to increase the expression 
of interferon-inducible pro-inflammatory genes.
Siiskonen et  al. describe the mysterious and unexpected 
functions of hyaluronan synthase 1 (HAS-1), which is less 
known and less explored than its two HAS-2 and HAS-3 enzyme 
“step  brothers,” which also engage in HA synthesis. As HAS-1 
embryonic gene deletion does not influence the normal pheno-
type, this raises the questions: are its functions compensated (by 
redundancy) by the two other HAS enzymes, and if so, why has 
HAS-1 has been preserved in the course of evolution?
Receptor (e.g., CD44) sensitivity to hyaluronan quantity and 
size provides a biosensor of the state of the microenvironment 
(inflammation, cancer stroma, or wound healing) surrounding 
the cell. Hence, to learn more on the chemical profile of HA in the 
context of these parameters or on technologies associated with 
its quantification, specification, isolation, and size determination 
in both fluids and tissues, it would be highly beneficial to read 
Cowman et al. communication.
Readers interested in the structural alternations associated 
with the HA-binding domain (HABD) of CD44 after HA binding, 
cannot miss Guvench’s chapter. The authors (Guvench et al.) per-
formed extensive all-atom explicit-solvent molecular dynamics 
(MD) simulations of HABD and the conclusions are presented in 
this communication. However, the HABD was analyzed indepen-
dently of the rest of the CD44 molecule, while the transmembrane 
domain and especially the cytoplasmic tail influence the binding 
affinity as well (2, 6). Furthermore, it should be recalled that in 
this study, the conclusions are limited to HABD interaction with 
HA oligomers, whereas larger HA molecules were not evaluated.
Monslow et  al. comprehensively reviewed the role of HA 
in health and disease, especially in relation to HA size. Their 
size definition for HA is formulated as follows: HMW-HA: 
>1000  kDa; intermediate (medium) molecular weight-HA 
(MMW-HA): 250–1000  kDa; LMW-HA: >10–250  kDa; and 
oligo-HA (<10 kDa). However, there is no consensus on these 
definitions and standardization of these values by an interna-
tional workshop is necessary. In general, there is a consensus 
that HMW-HA controls normal homeostasis and displays 
anti-inflammatory and anti-cancerous effects, with a few excep-
tions. Many researchers consider LMW-HA and oligo-HA pro-
inflammatory and pro-cancerous GAGs, as well as stimulators of 
pro-inflammatory cytokines. Yet, there are many contradictory 
findings. This confusion is related to the lack of consensus on 
size definition, polydispersity of HA commercial products (differ-
ent HA sizes in the same product), the use of HA from different 
animal sources or from different tissues, and, finally, the impurity 
of commercial products. These reservations must be taken into 
account whenever a new study on HA is undertaken.
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Four-methylumbelliferone (4-MU) is an HA-antagonizing 
product, described by Nagy et  al. The product inhibits HAS 
synthesis by reducing the availability of UDP-GlcUA to the 
enzyme, thus, interfering with HA synthesis and consequently 
with HA-related pathologies, such as cancer and autoimmunity. 
As 4-MU is an already approved drug called “hymecromone” for 
biliary spasm, the road to 4-MU therapy of inflammatory diseases 
and malignancy has been largely paved.
Hyaluronan and CD44 reside in the lipid rafts, cholesterol- 
and glycosphingolipid-enriched membrane microdomains that 
regulate the membrane receptors as well as signal delivery from 
the cell surface into the cell. Murai et al. examines in particular 
lipid raft regulation of HA binding to the CD44 of T lymphocytes 
and malignant cells, binding, which leads to rolling interactions 
on vascular endothelial cells, an important phase in inflammation 
and cancer development.
If the reader centers his/her interest on the inter-relationship 
between the tumor and its inflammatory microenvironment in 
context to HA, he/she can be referred to the article by Nikitovic 
et al. The authors focus their discussion on the influence of the 
cancer inflammatory environment on tumor growth, with spe-
cific emphasis on stromal HA.
The interplay between the tumor and its stromal microenvi-
ronment is also documented by Schwertfeger et al., using breast 
cancer as an example. The generation of a pro-tumorigenic 
inflammatory environment during breast cancer development 
requires LMW-HA-induced recruitment and activation of inflam-
matory macrophages. The macrophages release NFkB-regulated 
pro-inflammatory factors (IL-1β, IL-12, reactive oxygen species), 
normally involved in tissue repair. Hence, the cancer cells “stole” 
the inflammation supportive machinery from the wound healing 
process.
Such inter-relationships between the tumor and its micro-
environment are described also in hematological tumors. 
Gutjahr et  al. call our attention to the pro-cancerous survival 
(or anti-apoptotic) signals delivered by the tumor inflammatory 
environment, focusing on acute lymphocytic leukemia (CLL). 
Long-term survival and proliferation of CLL cells requires 
their dynamic interaction with stromal and immune cells in 
lymphoid organs. Interactions of HA with cell surface CD44 or 
RHAMM contribute to CLL cell localization, and hence to CLL 
pathophysiology. Deep mining of these complex interactions 
may reveal links more susceptible to therapeutic targeting, such 
as CD44v6, RHAMM, VLA-4, ZAP-70, or HAS (for details, see 
this communication).
Lee-Sayer et al. focus their attention on the inter-relationships 
between HA and CD44 in cells involved in the innate and adop-
tive immune system in the context of inflammation. Under innate 
inflammatory conditions, dendritic cells express HA on their 
membrane and T cells upregulate CD44. In the adoptive phase, 
interactions between the HA of the antigen-presenting dendritic 
cells and the activated CD44 of T lymphocytes may allow intimate 
contact between the co-stimulating molecules of the former and 
accessory molecules of the latter, leading to activation of the 
lymphocyte’s T cell receptor. Going one step further, the HA and 
the CD44 molecules may also be considered co-stimulating and 
accessory molecules.
If the reader wants to know how HMW-HA and LMW-HA 
are involved in allergic inflammation, he/she should focus on the 
communication by Kim et al. The reader can surmise, following 
extrapolation from the inflammation data, that HMW-HA is 
anti-allergic, whereas LMW-HA is pro-allergic. The mechanisms 
underlying these effects, including the role of microRNAs, are 
reported in detail.
McDonald and Kubes describe the cell trafficking roles on 
endothelial cells in the liver, which are different than those in 
other tissues. Recent evidence implicates serum-derived hyalu-
ronan-associated protein (SHAP) as an important co-factor that 
strengthens the binding of HA to CD44 under shear stress, result-
ing in improved cell extravasation. Finally, the authors indicate 
that HA–CD44 interaction supports not only destructive chronic 
inflammation but also the trafficking of stem cells that resolve 
the inflammation, the balance between the two determining the 
tissue’s fate.
Bourguignon and Bikle suggest that the interaction of large 
HA (>1000 kDa) with cell surface CD44 leads to Rac-signaling 
and normal keratinocyte differentiation, DNA repair, and survival 
function. On the other hand, the interaction of small/fragmented 
(10–100 kDa) HA (generated by UV irradiation) with cell surface 
CD44 stimulates RhoA/ROC activation, NFκB/Stat-3 signaling, 
and microRNA-21 production, resulting in proliferation and 
inflammation, as well as in the progression of squamous cell car-
cinomas (SCC). A balance that favors the “good” Rac-signaling 
over the “bad” RhoA signaling can be generated by Y27623, a 
ROK inhibitor, vitamin D, or by triggering HAS-2, which acti-
vates the production of large HA. These therapeutic approaches 
may be used for therapy of patients with UV irradiation-skin 
diseases (for more details, see the article).
Misra et al. comprehensively describe technologies that can be 
used to modulate the signals of HA–HA receptor interactions in 
favor of the patient. A sophisticated approach is Misra’s technol-
ogy relating to transferrin-coated nanoparticles, which include 
CD44v6 shRNA, to silence the CD44v6 gene in tumor cells 
expressing transferrin receptor. Readers, who seek information 
on this fascinating approach, or to other therapeutic strategies 
based on disrupting HA–CD44 interactions and subsequent 
signaling, are invited to read this chapter.
The use of a CD44-targeting peptide, Ac-KPSSPPEE-NH2, 
is another therapeutic strategy, documented by Finlayson, to 
combat CD44-associated pathological activities in experimental 
vascularized eye, tumor xenografts, or in clinical trials. If the 
reader wishes to know more on the peptide’s mechanism of 
action, it is recommended to read this chapter.
Jordan et al. focuses our attention on normal and aberrant cel-
lular signaling generated after interaction of HA with its receptor 
(mainly CD44), under different physiological and pathological 
settings. These include bacterial infection, viral infection, inter-
stitial lung disease, wound healing, chronic inflammation (auto-
immunity), and cancer. The outcome of such aberrant signaling is 
uncontrolled cell migration, cell proliferation, cell survival (e.g., 
of cancer cells), apoptosis [e.g., of β cells in type 1 diabetes; (12)], 
angiogenesis, and EMT, leading to different pathologies.
Both hematopoietic stem cells (HSCs) and leukemia stem 
cells (LSCs), also known as leukemia-initiating cells (LICs) seek 
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a “shelter” called a bone marrow “niche.” The niche maintains the 
“ stemness” of the host cells, i.e., supports their survival and hom-
ing as well as regulates the balance between their quiescence and 
growth. Once HSCs are transplanted into a leukemic patients, 
they eventually compete with LICs for lodging in the niche, 
engaging their cell surface CD44 in interaction with the HA of 
the niche. In this communication, Zöller raises the question: how 
can an advantage be imparted to the transplanted HSCs over the 
patient’s LICs in the context of HA–CD44 interaction, in view of 
their largely identical biological nature, when they compete for 
“shelter” in the same niche. The answer to the question may be 
found in this communication.
Orian-Rousseau’s communication is focused on the role of 
CD44 isoforms as co-receptors, especially for receptor tyrosine 
kinases (RTK). She further calls our attention to the involve-
ment of CD44 in Wnt signaling, both as a regulator of the Wnt 
receptor (via interaction with LRP6) or as a Wnt target gene, 
e.g., for CD44v6 or Met-RTK expression. Involvement of CD44 
in Wnt signaling, leading to EMT, is also discussed. Finally, 
Dr Orian-Rousseau speculates on the function of CD44 in cancer 
stem cells (CSCs), which has so far has been studied as a biomarker 
for these cells, but its role in CSCs remains elusive. Integration 
of the CD44v6 co-receptor (activated by HA ?) and Met-RTK 
(activated by hepatocyte growth factor) with Wnt signaling may 
explain what could be the role of CSC CD44 in colorectal cancer 
and perhaps other malignancies, i.e., by promotion of cell migra-
tion and metastasis.
In conclusion, the elephant unveiled in this e-book reveals 
a fascinating story about the HA–CD44 interaction, which not 
only exposes the underlying mechanism of this interaction but 
also allows identification of weak links, which can be targeted by 
various therapeutic approaches in both cancer and inflammatory 
diseases.
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